Am J Blood Res 2013;3(3):201-209
Review Article
Tailoring of chronic lymphatic leukemia therapy
Ashraf M Elhefni
Department of Internal Medicine, Hematology/Medical Oncology Unit, Faculty of Medicine, Zagazig University, Zagazig, Egypt
Received March 17, 2013; Accepted June 25, 2013; Epub August 19, 2013; Published August 30, 2013
Abstract: Chronic lymphocytic leukemia (CLL) remains an incurable disease, with all patients who require therapy destined to
relapse and understanding of the pathophysiology of chronic lymphocytic leukemia has advanced significantly. It is now clear
that chronic lymphocytic leukemia is a relatively proliferative disorder that requires the help of its microenvironment to be
maintained and to progress. The stimulation of the chronic lymphatic leukemia cell occurs in most, if not all, patients through
antigen stimulation via the B cell receptors. In addition, there is now a appreciation of the role of the p53 pathway leading to
chemoresistance and the elucidation of the molecular and intracellular signaling mechanisms of disease is just beginning to
facilitate the development of several targeted small molecules that promise to revolutionize the treatment of Chronic
lymphocytic leukemia. (AJBR1303002).
Keywords: Chronic lymphocytic leukemia, pathophysiology, target therapy
Address correspondence to: Dr. Ashraf M Elhefni, Department of Internal Medicine, Hematology/Medical Oncology Unit,
Faculty of Medicine, Zagazig University, Zagazig, Egypt. Tel: +201005766415; Fax: +20552330211; E-mail:
Elhefny70@zu.edu.eg; Elhefny70@yahoo.co.uk
Review Article
Tailoring of chronic lymphatic leukemia therapy
Ashraf M Elhefni
Department of Internal Medicine, Hematology/Medical Oncology Unit, Faculty of Medicine, Zagazig University, Zagazig, Egypt
Received March 17, 2013; Accepted June 25, 2013; Epub August 19, 2013; Published August 30, 2013
Abstract: Chronic lymphocytic leukemia (CLL) remains an incurable disease, with all patients who require therapy destined to
relapse and understanding of the pathophysiology of chronic lymphocytic leukemia has advanced significantly. It is now clear
that chronic lymphocytic leukemia is a relatively proliferative disorder that requires the help of its microenvironment to be
maintained and to progress. The stimulation of the chronic lymphatic leukemia cell occurs in most, if not all, patients through
antigen stimulation via the B cell receptors. In addition, there is now a appreciation of the role of the p53 pathway leading to
chemoresistance and the elucidation of the molecular and intracellular signaling mechanisms of disease is just beginning to
facilitate the development of several targeted small molecules that promise to revolutionize the treatment of Chronic
lymphocytic leukemia. (AJBR1303002).
Keywords: Chronic lymphocytic leukemia, pathophysiology, target therapy
Address correspondence to: Dr. Ashraf M Elhefni, Department of Internal Medicine, Hematology/Medical Oncology Unit,
Faculty of Medicine, Zagazig University, Zagazig, Egypt. Tel: +201005766415; Fax: +20552330211; E-mail:
Elhefny70@zu.edu.eg; Elhefny70@yahoo.co.uk
| AJBR Copyright © 2011-present, All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711, USA |
 |  |  |  |  |  |  |